Complement Pathway, Classical
"Complement Pathway, Classical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
Descriptor ID |
D003171
|
MeSH Number(s) |
G12.274.698
|
Concept/Terms |
Complement Pathway, Classical- Complement Pathway, Classical
- Classical Complement Activation Pathway
- Complement Activation Pathway, Classical
- Classical Complement Pathway
|
Below are MeSH descriptors whose meaning is more general than "Complement Pathway, Classical".
Below are MeSH descriptors whose meaning is more specific than "Complement Pathway, Classical".
This graph shows the total number of publications written about "Complement Pathway, Classical" by people in this website by year, and whether "Complement Pathway, Classical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2005 | 1 | 1 | 2 |
2008 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 2 | 1 | 3 |
2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement Pathway, Classical" by people in Profiles.
-
Lewis LA, Panicker S, DeOliveira RB, Parry GC, Ram S. Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against Neisseria meningitidis and Streptococcus pneumoniae. Immunohorizons. 2019 11 05; 3(11):519-530.
-
DeZern AE, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2014 Oct; 42(10):857-61.e1.
-
Agarwal S, Vasudhev S, DeOliveira RB, Ram S. Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides. J Immunol. 2014 Aug 15; 193(4):1855-63.
-
Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, Lappeg?rd KT, Brekke OL, Lambris JD, Dam?s JK, Latz E, Mollnes TE, Espevik T. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol. 2014 Mar 15; 192(6):2837-45.
-
Rosadini CV, Ram S, Akerley BJ. Outer membrane protein P5 is required for resistance of nontypeable Haemophilus influenzae to both the classical and alternative complement pathways. Infect Immun. 2014 Feb; 82(2):640-9.
-
Gulati S, Agarwal S, Vasudhev S, Rice PA, Ram S. Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J Immunol. 2012 Apr 01; 188(7):3416-25.
-
Ghebremariam YT, Engelbrecht G, Tyler M, Lotz Z, Govender D, Kotwal GJ, Kahn D. Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats. J Surg Res. 2010 Apr; 159(2):747-54.
-
Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008 Mar 01; 180(5):3426-35.
-
Kulkarni AP, Ghebremariam YT, Kotwal GJ. Curcumin inhibits the classical and the alternate pathways of complement activation. Ann N Y Acad Sci. 2005 Nov; 1056:100-12.
-
Ghebremariam YT, Odunuga OO, Janse K, Kotwal GJ. Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathways. Ann N Y Acad Sci. 2005 Nov; 1056:113-22.